ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
May 08 2024 - 1:00PM
ImmuCell Corporation (Nasdaq: ICCC)
(“ImmuCell” or the “Company”), a growing animal health company that
develops, manufactures and markets scientifically proven and
practical products that improve the health and productivity of
dairy and beef cattle, expects to report unaudited financial
results for the quarter ended March 31, 2024 after the market
closes on Tuesday, May 14, 2024.
The Company is planning to host a conference call the next
morning, Wednesday, May 15, 2024, at 9:00 AM ET to review the
unaudited financial results. This date has been pushed back five
days from the original date of May 10, 2024. Interested parties can
access the conference call by dialing (844) 855-9502 (toll free) or
(412) 317-5499 (international) at 9:00 AM ET. A teleconference
replay of the call will be available until May 22, 2024 at (877)
344-7529 (toll free) or (412) 317-0088 (international), utilizing
replay access code #2581533.
The Company anticipates no change to the preliminary sales
results for the first quarter ended March 31, 2024 that were
disclosed on April 9, 2024. The Company expects to file its
Quarterly Report on Form 10-Q after the market closes on May 14,
2024.
Investors are encouraged to review the Company’s updated
Corporate Presentation slide deck that provides an overview of the
Company’s business which can be accessed under the “Investors” tab
of the Company’s website at www.immucell.com, or by request to the
Company. An updated version of the slide deck will be made
available under the “Investors” tab of the Company’s website after
the market closes on Tuesday, May 14, 2024.
About ImmuCell:ImmuCell Corporation's
(Nasdaq: ICCC) purpose is to create scientifically
proven and practical products that improve the health and
productivity of dairy and beef calves. ImmuCell manufactures and
markets First Defense®, providing
Immediate Immunity™ to newborn dairy and beef
calves, and is in the late stages of developing
Re-Tain®, a novel treatment for subclinical
mastitis in dairy cows with a no milk discard claim that provides
an alternative to traditional antibiotics. Press releases and other
information about the Company are available at:
http://www.immucell.com.
Contacts: |
Michael F. Brigham, President and CEO |
|
ImmuCell Corporation |
|
(207) 878-2770 |
|
|
|
Joe Diaz, Robert Blum and Joe
Dorame |
|
Lytham Partners, LLC |
|
(602) 889-9700 |
|
iccc@lythampartners.com |
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ImmuCell (NASDAQ:ICCC)
Historical Stock Chart
From Sep 2023 to Sep 2024